Two Onc Docs Immune Thrombocytopenia Purpura ( ITP) 2025 UPDATE
14 snips
Sep 22, 2025 Explore the world of Immune Thrombocytopenia Purpura (ITP) in this enlightening discussion. Learn about the mechanisms of antibody-mediated platelet destruction and the factors that can lead to this condition. Discover the clinical signs to watch for and the comprehensive diagnostic approach used by experts. The conversation dives into treatment options, from steroids to advanced therapies like TPO agonists and rituximab. It's a crucial update packed with insights relevant for heme consults and board reviews.
AI Snips
Chapters
Transcript
Episode notes
ITP Mechanism And Targets
- ITP is antibody-mediated platelet destruction targeting platelet surface glycoproteins like GP2B and GP1B9.
- This immune clearance occurs via splenic or hepatic macrophage activation leading to thrombocytopenia.
Primary vs Secondary Causes
- Most ITP is primary and idiopathic but can follow viral illness or immunization by 1–3 weeks.
- Secondary causes include drugs, infections, autoimmune diseases, and hematologic malignancies like CLL.
Epidemiology And Risk Groups
- ITP peaks in childhood and again in adulthood and shows a female predominance.
- It is one of the most common acquired bleeding disorders and common autoimmune blood conditions in adults.